140 related articles for article (PubMed ID: 32918927)
1. Long-term efficacy and safety of a new botulinum toxin type A preparation in mouse gastrocnemius muscle.
Na J; Lee E; Kim YJ; Choi MJ; Kim SY; Nam JS; Yun BJ; Kim BJ
Toxicon; 2020 Nov; 187():163-170. PubMed ID: 32918927
[TBL] [Abstract][Full Text] [Related]
2. A pilot study comparing the efficacy of two formulations of botulinum toxin type A for muscular calves contouring.
Wanitphakdeedecha R; Ungaksornpairote C; Kaewkes A; Sathaworawong A; Vanadurongwan B; Lektrakul N
J Cosmet Dermatol; 2018 Dec; 17(6):984-990. PubMed ID: 30203534
[TBL] [Abstract][Full Text] [Related]
3. A pharmacodynamic comparison study of different botulinum toxin type A preparations.
Kim SB; Ban B; Jung KS; Yang GH
Dermatol Surg; 2013 Jan; 39(1 Pt 2):150-4. PubMed ID: 23301818
[TBL] [Abstract][Full Text] [Related]
4. The rat Digit Abduction Score (DAS) assay: a physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis.
Broide RS; Rubino J; Nicholson GS; Ardila MC; Brown MS; Aoki KR; Francis J
Toxicon; 2013 Sep; 71():18-24. PubMed ID: 23707612
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of new botulinum toxin identified in CCUG 7968 strain.
An Y; Kim YJ; Kim CS; Yim H; Kim M; Lee EK; Oh HJ; Han JH; Yoo E; Kim S; Woo J; Moore ERB; Jung JY; Park W
Appl Microbiol Biotechnol; 2021 Dec; 105(23):8727-8737. PubMed ID: 34716460
[TBL] [Abstract][Full Text] [Related]
6. How muscles recover from paresis and atrophy after intramuscular injection of botulinum toxin A: Study in juvenile rats.
Shen J; Ma J; Lee C; Smith BP; Smith TL; Tan KH; Koman LA
J Orthop Res; 2006 May; 24(5):1128-35. PubMed ID: 16602109
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of two formulations of botulinum toxin type A for masseter reduction: a split-face comparison study.
Wanitphakdeedecha R; Ungaksornpairote C; Kaewkes A; Sathaworawong A; Lektrakul N; Manuskiatti W
J Dermatolog Treat; 2017 Aug; 28(5):443-446. PubMed ID: 27884065
[TBL] [Abstract][Full Text] [Related]
8. Characterization of diffusion and duration of action of a new botulinum toxin type A formulation.
Stone HF; Zhu Z; Thach TQ; Ruegg CL
Toxicon; 2011 Aug; 58(2):159-67. PubMed ID: 21658400
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of long-term botulinum toxin treatment for acquired cervical dystonia: a 25-year follow-up.
Petracca M; Lo Monaco MR; Ialongo T; Di Stasio E; Cerbarano ML; Maggi L; De Biase A; Di Lazzaro G; Calabresi P; Bentivoglio AR
J Neurol; 2023 Jan; 270(1):340-347. PubMed ID: 36068376
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin A (Botox) and sweating-dose efficacy and comparison to other BoNT preparations.
Schlereth T; Mouka I; Eisenbarth G; Winterholler M; Birklein F
Auton Neurosci; 2005 Feb; 117(2):120-6. PubMed ID: 15664565
[TBL] [Abstract][Full Text] [Related]
11. Field effect of two commercial preparations of botulinum toxin type A: a prospective, double-blind, randomized clinical trial.
Hexsel D; Brum C; do Prado DZ; Soirefmann M; Rotta FT; Dal'Forno T; Rodrigues TC
J Am Acad Dermatol; 2012 Aug; 67(2):226-32. PubMed ID: 22041253
[TBL] [Abstract][Full Text] [Related]
12. Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia.
de Kort LM; Kok ET; Jonges TN; Rosier PF; Bosch JL
Urology; 2012 Oct; 80(4):889-93. PubMed ID: 22854138
[TBL] [Abstract][Full Text] [Related]
13. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
[TBL] [Abstract][Full Text] [Related]
14. Comparative Pharmacodynamics of Three Different Botulinum Toxin Type A Preparations following Repeated Intramuscular Administration in Mice.
Byun J; Kwak S; Kwon JH; Shin M; Lee DK; Rhee CH; Kang WH; Oh JW; Cruz DJM
Toxins (Basel); 2022 May; 14(6):. PubMed ID: 35737026
[TBL] [Abstract][Full Text] [Related]
15. Muscle volume alterations in spastic muscles immediately following botulinum toxin type-A treatment in children with cerebral palsy.
Williams SA; Reid S; Elliott C; Shipman P; Valentine J
Dev Med Child Neurol; 2013 Sep; 55(9):813-20. PubMed ID: 23789782
[TBL] [Abstract][Full Text] [Related]
16. Onabotulinumtoxin A (ONA-BoNT/A) in the treatment of chronic migraine.
Domitrz I; Sławek J; Słowik A; Boczarska-Jedynak M; Stępień A; Rejdak K; Gierczyński J; Rożniecki J
Neurol Neurochir Pol; 2022; 56(1):39-47. PubMed ID: 34477213
[TBL] [Abstract][Full Text] [Related]
17. Clinical differences between botulinum neurotoxin type A and B.
Bentivoglio AR; Del Grande A; Petracca M; Ialongo T; Ricciardi L
Toxicon; 2015 Dec; 107(Pt A):77-84. PubMed ID: 26260691
[TBL] [Abstract][Full Text] [Related]
18. Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer.
Chen JJ; Dashtipour K
Pharmacotherapy; 2013 Mar; 33(3):304-18. PubMed ID: 23400888
[TBL] [Abstract][Full Text] [Related]
19. Is spastic muscle echo intensity related to the response to botulinum toxin type A in patients with stroke? A cohort study.
Picelli A; Bonetti P; Fontana C; Barausse M; Dambruoso F; Gajofatto F; Girardi P; Manca M; Gimigliano R; Smania N
Arch Phys Med Rehabil; 2012 Jul; 93(7):1253-8. PubMed ID: 22502807
[TBL] [Abstract][Full Text] [Related]
20. Comparison of neurotoxic potency between a novel chinbotulinumtoxinA with onabotulinumtoxinA, incobotulinumtoxinA and lanbotulinumtoxinA in rats.
Feng Y; Liu W; Pan L; Jiang C; Zhang C; Lu Y; Nie Z; Jin L
Drug Des Devel Ther; 2017; 11():1927-1939. PubMed ID: 28721012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
